Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Drug: bevacizumab [Avastin]

Study type: Observational

Funder types: Industry

Identifiers

NCT01089413

ML25117

Details and patient eligibility

About

This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin] treatment in patients with metastatic colorectal cancer. Data will be collected for approximately 34 months. The target sample size is >300 patients.

Enrollment: 201 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patients =/<18 years of age
• metastatic colorectal cancer
• patients for whom the physician has prescribed bevacizumab [Avastin] for the treatment of 1st line metastatic colorectal cancer
• patients, who have given written informed consent

Exclusion criteria

• hypersensitivity to recombinant human or humanised antibodies
• pregnancy or breast-feeding

Trial design

201 participants in 1 patient group

Cohort

Treatment:

Drug: bevacizumab [Avastin]